Drug Metabolism in Drug Design and Development Basic Concepts and Practice
Reactive Metabolites or Intermediates Reactive metabolites are chemically unstable and often rapidly bind to proteins or glutath ...
findings ofin vitrostudies. Negative findings fromin vitrowork can help eliminate the need for relatedin vivo studies. Proper us ...
with respect to time and enzyme concentrations. The 2006 draft guidance for drug interaction studies adds CYP2B6 and CYP2C8 as r ...
in vivodrug interaction study may not be needed. The ratio of [I]/Kionly predicts the likelihood of anin vivointeraction, not th ...
clinical dose as inhibitor concentrations [I] for prediction. This is a conservative way to calculate the ratio. Table 7.5 lists ...
Ki. If the inhibition process is strictly noncompetitive, the IC 50 should be equal to theKi. For competitive inhibition, IC 50 ...
7.4.1.5 Induction The knowledge of mechanisms and experimental condi- tions for drug induction studies has greatly advanced in r ...
study of Japanese cancer patients revealed that those with variant UGT1A1 alleles were at significantly higher risk of severe ad ...
ratio<2 is considered as negative for P-gp involvement. Additionalin vitro transporter studies will be dependent on the valid ...
approved dose and the shortest dosing interval in humanin vivo studies (Table 7.7). This classification is quite useful since in ...
between ritonavir and fluticasone (http://www.fda.gov/cder/foi/label/2004/ 20549slr016,20548slr020,20121slr030_flonase_lbl.pdf). ...
of St John’s wort on human CYP enzymes, in which caffeine, tolbutamide, dextromethorphan, oral and intravenous midazolam were us ...
7.4.2.5 Outcomes The FDA 2006 draft guidance for drug interactions states that the results of drug–drug interaction studies shou ...
another study, 20 or 40 mg conivaptan was given orally twice a day from Day 2 to Day 6 and simvastatin 60 mg was given orally on ...
research in the pharmaceutical industry although the discussions on how to conduct metabolite safety testing will continue. Meta ...
Bruce MA, Stephen DH, Haehner-Daniels DB, Gorski JC. In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab D ...
and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 1998;64:237–247. Guengerich FP. Saf ...
dynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003b;46:347–351. O ...
Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction poten ...
PART II ROLE OF DRUG METABOLISM IN THE PHARMACEUTICAL INDUSTRY ...
«
8
9
10
11
12
13
14
15
16
17
»
Free download pdf